Search

Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017
100-e1500674849526.jpeg
Extremities

Paragon 28® expands innovative product portfolio with the launch of the PROMO™ Triplanar Hallux Valgus Correction System

July 21, 2017 OrthoSpineNews

ENGLEWOOD, Colo., July 21, 2017 /PRNewswire/ — Since its inception, Paragon 28 has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation that help to streamline procedures, allow surgeons flexibility in technique and approach, and facilitate reproducible results benefitting both the surgeon and patient.

PROMO or Proximal Rotational Metatarsal Osteotomy is a hallux valgus correction system designed to allow complete bunion correction in multiple planes. Recent studies have shown that up to 87% of hallux valgus (bunion) deformities contain a frontal plane rotational deformity.1  While traditional single-plane procedures such as the scarf or chevron osteotomes only correct the transverse deformity, PROMO simultaneously corrects the metatarsal internal pronation as well as the varus deformity through a single, oblique osteotomy.

The patent-pending PROMO System contains a series of custom jigs and implants utilized in the measurement, construction and fixation of an oblique plane osteotomy specific to the patient’s deformity. Unique plates are included that are sized and shaped around the oblique angulation of the osteotomy. PROMO also includes a PRECISION™ guided system which enables the user to place a cross screw across the osteotomy while avoiding hardware collision with the plating construct.

Features & Benefits:

  • Corrects all deformity parameters including rotation in the frontal plane
    • May help decrease chance of recurrence2
  • Single Oblique Osteotomy
    • Reduces the likelihood of shortening which can help prevent transfer metatarsalgia
    • Osteotomy allows for placement of an interfragmentary screw which increases the rigidity of the construct
  • Custom jigs aid in construction of the oblique plane osteotomy
    • Repeatable and streamlined technique
  • Avoids fusing the first TMT joint
    • Helps sustain patient joint health

Paragon 28 is grateful for the significant contributions Dr. Emilio Wagner, MD, and Dr. Pablo Wagner, MD, made as surgeon designers of this system.

For additional information on the PROMO™ Triplanar Correction System, visit the Paragon 28 website at www.Paragon28.com.

1  Kim Y, Kim JS, Young KW, et al. A new measure of tibial sesamoid position in hallux valgus
in relation to the coronal rotation of the first metatarsal in CT scans. Foot Ankle Int. 2015; 36(8): 944-52.

2  Wagner P, Wagner E, Ortiz C. Rotational osteotomy for hallux valgus.
A new technique for primary and revision cases. Tech Foot Ankle Surg. 2017; 16(1): 3-10

Contact: Jim Edson, Director of Product Management and Marketing, jedson@paragon28.com

 

SOURCE Paragon 28

Related Links

http://www.Paragon28.com

CONTINUE READING
merger-small.jpg
Biologics

Tissue Regenix Announces Proposed Acquisition of CellRight Technologies

July 21, 2017 OrthoSpineNews

July 21, 2017

SAN ANTONIO–(BUSINESS WIRE)–Tissue Regenix, the UK-based regenerative medical devices company, today announced the proposed acquisition of CellRight Technologies, a U.S. regenerative medicine company based in San Antonio, TX. This acquisition would bring together two highly complementary technology and product platforms focused on soft-tissue regeneration and regenerative bone matrices, respectively.

The deal accelerates both companies’ vision to becoming a global leader in regenerative medicine by accelerating growth and penetration into key U.S. markets. The combined group will have a highly complementary product offering with CellRight Technologies’ existing orthopedic portfolio, based on human-derived bone graft products, and Tissue Regenix’s soft tissue products based on its patented decellularisation dCELL® Technology (dCELL®), a multi-tissue regenerative medical platform.

The combined group provides CellRight Technologies with the infrastructure of a larger, multi-national organization and a platform to enter new geographies. CellRight Technologies’ human tissue-based products, including Matrix OI, will expand the current Tissue Regenix portfolio, which includes DermaPure® for wound care applications. Additionally, CellRight Technologies’ existing tissue bank in San Antonio, TX, provides Tissue Regenix with a purpose built U.S. base to self-manufacture products utilizing its patented dCELL® process.

Combined with the capabilities of CellRight Technologies’ osteobiologics, this acquisition positions Tissue Regenix to launch into the U.S. orthopedics market in early 2018 with a focus on ligament reconstruction, initially addressing anterior cruciate ligament repair, through OrthoPure® HT, a decellularised human tendon.

“We are excited by the huge potential that this acquisition brings for the advancement of regenerative medicine to our patients globally,” said Antony Odell, CEO of Tissue Regenix. “We are combining two highly complementary companies that are committed to developing a robust portfolio of products and we are poised for rapid growth through our existing product offering with plans for multiple U.S. launches over the next two years.”

CellRight Technologies has seen tremendous success in the U.S., including leveraging strong relationships with orthopedics and sports medicine companies. Founder and CEO Jesus Hernandez has been at the heart of research and development for the CellRight Technologies product line.

“Becoming part of the Tissue Regenix family is an exciting and important milestone for our company,” said Jesus Hernandez, founder and CEO of CellRight Technologies. “With the combined talent and expertise in biologics, we look forward to continuing to lead regenerative medicine, bringing our patients and healthcare partners the products and innovation which enhance their lives. We are all excited at the potential of what we will be able to accomplish together.”

For more information about Tissue Regenix, please visit http://www.tissueregenix.com/.

Important notice

The information contained herein is not for release, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. This document (and the information contained herein) does not contain or constitute an offer of securities for sale, or solicitation of an offer to purchase securities, in the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States unless the securities are registered under the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of the securities will be made in the United States.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) Technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

About CellRight Technologies

CellRight Technologies is the industry leader of osteoinductive matrices and is committed to providing clinicians and their patients with verified osteoinductive implants known to positively impact patient and fusion outcomes. In-vivo and in-vitro testing to verify osteoinductivity is performed post-sterilization by an independent testing laboratory using validated osteoinductivity test methods.

Contacts

Racepoint Global
Jeff Stoecker, +1-617-624-3424
jstoecker@racepointglobal.com

CONTINUE READING
189-1.jpg
BiologicsTop Stories

Singapore launches $13M 3D printing center with focus on medical research

July 21, 2017 OrthoSpineNews

Jul 21, 2017 | By Tess

A new 3D printing center with a focus on healthcare research was inaugurated in Singapore this morning. Called the National University of Singapore Centre for Additive Manufacturing (AM.NUS), the new facility is initially being funded by a grant of S$18 million (around $13,208,102) provided by NUS, the National Additive Manufacturing Innovation Cluster (NAMIC), and the Singapore Economic Development Board (EDB).

Researchers at AM.NUS, which was launched earlier today by Mr. Amrin Amin, a Parliamentary Secretary at the Ministry of Home Affairs and Ministry of Health, will reportedly work alongside the NUS’ Yong Loo Lin School of Medicine, as well as its Faculties of Engineering, Science, and Dentistry, and its School of Design and Environment.

The goal of establishing the new additive manufacturing center is to advance 3D printing technologies in the fields of biomedicine and healthcare and to “boost” NUS’ standing in the field of biomedical additive manufacturing.

“The NUS Centre for Additive Manufacturing will play a critical role in supporting Singapore’s vision of becoming a leading AM hub,” commented Professor Jerry Fuh Ying-Hsi, Co-Director of AM.NUS and the Thrust Lead of Restorative Repair & Implants from the Department of Mechanical Engineering at the NUS Faculty of Engineering.

“Through this inter-faculty pooling of expertise, we hope to boost technology capabilities as well as advance intellectual property development and commercialization of AM-enabled biomedical technologies.”

The new AM center will focus its research on a number of specific areas, including the development of customized 3D printed surgical instruments, simulators, and functional prosthetics; 3D printing-enabled customized medicine (i.e. personalized drug formulations, dosages, and drug release); advancing tissue repair using 3D printed scaffolds and tissue engineering; developing restorative repairs and implants with ceramic and metal 3D printing; and oral health and craniofacial applicaitons, which will be conducted with the NUS Faculty of Dentistry.

 

READ THE REST HERE

CONTINUE READING
spinal-fusion-surgery-nerve-injury.jpg
RegulatorySpineTop Stories

Medtronic Announces Infuse Settlements

July 21, 2017 OrthoSpineNews

Walter Eisner • Thu, July 20th, 2017

Medtronic plc says it has reached an agreement with “substantially all” remaining claimants involving the Infuse bone graft product.

In a June 27, 2017 10K filing with the SEC, the company announced the agreements with approximately 6,000 claimants. The company also said it has set aside $300 million for “certain litigation charges” in the filing.

The company had previously disclosed reaching settlements in more than 4,000 Infuse patient lawsuits. In December 2016, a judge in St. Louis cleared the way for the first jury trial involving personal injuries allegedly caused by Infuse. That trial could have opened sealed internal documents that could have been used in other trials.

According to the Minneapolis Star Tribune, the company paid at least $85 million in a settlement to shareholders in 2012 to resolve allegations that it failed to reveal that most sales of Infuse were for off-label surgeries. In 2014, Medtronic said it paid $22 million to 950 injured Infuse patients. The company denied wrongdoing in each settlement.

Remaining Investigations

While the announcement settles private claims, the company is still under investigation by various state attorneys general who have issued subpoenas or document requests in Massachusetts, California, Oregon, Illinois, and Washington seeking more information regarding the Infuse device.

 

READ THE REST HERE

 

CONTINUE READING
1-3-e1500652573807.jpeg
Sports MedicineTop Stories

Invibio and Carbofix Partnering With UK Olympic Sprinter James Ellington on New “Passion For Progress” Initiative

July 21, 2017 OrthoSpineNews

THORNTON CLEVELEYS, England, July 13, 2017 /PRNewswire/ —

UK Olympic sprinter James Ellington has joined forces with the UK´s Invibio Biomaterial Solutions and CarboFix Orthopedics on his road to recovery and his overall ambition to return to the world stage of athletic competition after a devastating motorcycle accident in Tenerife earlier this year.

(Photo: http://mma.prnewswire.com/media/535235/Invibio_Biomaterial_Solutions.jpg )

The two companies and the athlete share a passion for progress and pushing boundaries; for James Ellington, mentally and physically first in sport and now in recovery, and for CarboFix and Invibio with innovative biomaterials and devices that have the potential to change the treatment of trauma fractures. For patients recovering from traumatic injuries this could serve as an inspiration not to lose track of their goals and passion.

Changes in destiny couldn´t be more pronounced for an athlete like James Ellington, who suddenly turned from being a world-class, elite sprinter training for his next competition to a patient in recovery facing an unknown future. However, even the life-changing experience of a severe head-on collision of his motorbike with a car hasn’t stopped James Ellington from fighting for his goals, despite having his legs and pelvis completely smashed.

“In extreme situations, it’s important not to lose faith and to consider all (therapeutic) options available,” explains Ellington. “I had a severe tibia fracture, and was offered two choices to fix it: a traditional Titanium nail or a Carbofix nail using a relatively new, but promising carbon fibre, composite technology. For me, it’s all about giving myself the best chance of achieving my goal and returning to competitive athletics. I chose the Carbofix nail because it’s lighter weight and for its faster healing potential.” Continues Ellington, “The rod is made from a new composite polymer. It’s strong, in a way that’s similar to metal implants, but not as stiff, which means it has the capability to stress the bone more and provide some micro-motion, so it works more like natural bone. The idea is that this will help support a quicker recovery – which is what convinced me this was the right path for me.” The sprinter nevertheless considers himself lucky: because he survived, is not paralyzed, is walking again and is so far on a good recovery path that may also include running in the future.

With trauma implants made from Invibio’s PEEK-OPTIMA™ Ultra-Reinforced, a composite polymer, CarboFix Orthopedics is hoping to support James and other patients in a similar position. Ron Szekely, the company´s Vice President of Sales and Marketing, says: “The aim itself to get back on track is fantastic, whether that’s the athletic track or returning to other individual recovery goals. This can be an important driver for rehabilitation. In addition to dedication and enthusiasm, patients need to have access to innovative medical devices that can support this. At CarboFix we believe in the potential of changing trauma treatment to improve the quality of life for many patients.”

Coming back (on track): high quality of life is an important aspect for recovery

“James Ellington´s passion for progress is the common denominator and connecting link between himself and Invibio,” explains Medical Business Unit Director, John Devine of Invibio Biomaterial Solutions. “Metals have been used to treat trauma fractures for decades, but patient demands for a quicker recovery with fewer device breakages coupled with the global increase in patient risk factors such as obesity and diabetes mean we need to be open to progress. That includes being open to the possibility that new innovative carbon fibre reinforced devices made from less stiff materials could really change how successful surgery and patient recovery is. The medical (device) industry itself very often and for good reasons, has to make small albeit important steps, to overcome challenges and achieve substantial progress towards the ultimate objective of improving patient outcomes and quality of life. James knows exactly how that feels and his positive attitude and firm belief in capabilities and future performance is another point we have in common.”

Inspiring people to achieve new records

This “passion for progress” after a traumatic injury or challenging operation is a theme supported by the two companies and centering on James Ellington´s hope to become an active athlete again. Together, Ellington, CarboFix and Invibio are pleased that James has already achieved so much in the months since the accident. The progress and hope shown by James Ellington could also help and inspire patients and trauma surgeons alike – whether Ellington is a pioneer by being an Olympic athlete sprinter again, or simply back and participating in the race of life.

About CarboFix

CarboFix Orthopedics, is the world-wide leader in developing, manufacturing and marketing orthopedic implants made of continuous Carbon-Fiber reinforced polymers.

The products company currently markets around the world its Piccolo Trauma and Carboclear spine lines.

CarboFix is working worldwide through its distributor network and through its subsidiaries in the US, China and Israel.
https://www.carbo-fix.com/

About Invibio Biomaterial Solutions
Invibio, a Victrex plc company, is a global leader in providing high performance biomaterial solutions to medical device manufacturers.  The company provides PEEK-OPTIMA™ polymers, advanced technical research and support and manufacturing of components for spine, trauma and orthopedic medical segments for the development of long implantable medical devices. Today, Invibio’s PEEK-OPTIMA™ polymers are used in around nine million implanted devices worldwide.

INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies.  All rights reserved.

About Victrex plc

Victrex, headquartered in the UK, is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years’ experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at http://www.victrexplc.com

Copyright ©2017 Invibio Ltd.

SOURCE Invibio Biomaterial Solutions

CONTINUE READING
sports-injuries-s3-torn-acl-1.jpg
Sports MedicineTop Stories

Smith & Nephew joins forces with Imperial’s Biomechanics Group

July 21, 2017 OrthoSpineNews

19 July 2017/by Naomi Black

The medical device giant Smith & Nephew have signed a 3-year partnership with a research group in the Department of Mechanical Engineering to find new ways to support one of our most important joints.

With an increasing participation in sport, and a trend to keep active later in life, the treatment of sports injuries of the knee has been identified by Smith & Nephew as one offering high growth opportunities.

The USD $1m research study is led by Professor Andrew Amis, Professor of Orthopaedic Biomechanics and leader of The Biomechanics Group, who already has a long-standing working relationship with the company.  His expertise with artificial ligaments and total and partial knee prostheses as well as field experience working directly with surgeons has set the groundwork for this latest agreement.

 

READ THE REST HERE

 

CONTINUE READING
1-antibioticre-1.jpg
Recon

Antibiotic-Releasing Polymer May Help Eradicate Joint Implant Infection

July 21, 2017 OrthoSpineNews

July 19, 2017 – Source: Massachusetts General Hospital

In the new approach to treating prosthetic joint infection, developed by Massachusetts General Hospital investigators, the infected prosthesis and affected tissue are removed and the new prosthesis, incorporating an antibody-releasing polymer, is implanted in a single procedure. The antibiotic — in this example vancomycin — is released over time to eradicate any bacteria that remain and prevent future infection. Courtesy of Jeremy Vincentius Suhardi, Harris Orthopædics Laboratory, Massachusetts General Hospital.

A team of Massachusetts General Hospital (MGH) investigators has developed an antibiotic-releasing polymer that may greatly simplify the treatment of prosthetic joint infection. In their recent report published in Nature Biomedical Engineering, the researchers describe how implants made from this material successfully eliminated two types of prosthetic infection in animal models.

“Currently, most infections involving total joint replacement prostheses require a two-stage surgery, in which the patient’s daily activities are largely compromised for four to six months,” says Orhun Muratoglu, PhD, director of the Harris Orthopedics Laboratory in the MGH Department of Orthopedic Surgery, a co-author of the report. “Our finding that polyethylene, the most commonly used weight-bearing surface in total joint surgery, can be made to safely and effectively release antibiotics implies that fully weight-bearing implants made with this material could be used to treat infection in a single procedure, reducing both the inconvenience and the risk of complications for patients.”

 

READ THE REST HERE

CONTINUE READING
1-1-1.jpeg
Biologics

Collagen Matrix Celebrates 20 Years of Science, Technology and Innovation

July 20, 2017 OrthoSpineNews

OAKLAND, N.J., July 18, 2017 /PRNewswire/ — It started with an idea that transformed into a success story, 20 years in the making. Today, Collagen Matrix, celebrating its 20th anniversary, has developed collagen and mineral based medical devices that have helped patients worldwide with over 7.5 million products sold. The Company has grown from a start-up business with a handful of employees to nearly 200 team members located in two state-of-the-art facilities totaling 73,000 sq. ft. and now distributes products worldwide.

Advancing the Science
The Company’s passion for advancing the science of tissue repair and regeneration has helped the healthcare industry by designing, developing and manufacturing innovative medical devices that support the body’s natural ability to regenerate. Collagen Matrix has built two decades of science, technology and innovation into its robust product portfolio in five key therapeutic areas – Dental, Spine, Orthopaedic, Dural Repair and Nerve Repair.

Teamwork, Leadership & Evolution
Collagen Matrix is very proud of its evolution and advancement, which shows how determination, perseverance and teamwork can provide significant success. “To see what has transpired here in just 20 years is an incredible achievement for this organization,” said Bart J. Doedens, Chief Executive Officer. “We continue to build on our capabilities to help our customers provide products that solve clinical challenges, and we confidently look forward to what the next 20 years will bring.”

“The past two decades have been an extraordinary journey,” said Shu-Tung Li, Ph.D., Founder and Chief Scientific Officer, “Our focused commitment to R&D continues to position us as the expert in producing collagen based products and has facilitated the Company’s success. We wouldn’t be here without the dedication and commitment of our employees and support of our customers.”

New Branding, Website & Celebration
To celebrate, the Company has launched new branding for its five Business Units and developed a technologically savvy new website, www.CollagenMatrix.com, with interactive product videos, downloadable marketing and sales literature and numerous valuable resources for its users. A formal event is planned for the fall where the Collagen Matrix team members will celebrate the Company’s success.

About Collagen Matrix
Collagen Matrix, Inc., founded in 1997, delivers a full line of the highest-quality collagen and mineral based medical devices that support the body’s natural ability to regenerate. The Company currently manufactures finished medical devices in the areas of Dental, Spine, Orthopaedic, Dural Repair and Nerve Repair Surgery. The evolution of the Company’s leadership, proprietary technologies, manufacturing expertise and product portfolio has established a solid foundation for continued growth. Opportunities continue to exist for collaboration through Product Distribution, Product Development and Contract Manufacturing. More information about Collagen Matrix can be found at www.CollagenMatrix.com.

Contact: Margo Lane
201-405-1477
mlane@collagenmatrix.com

SOURCE Collagen Matrix, Inc.

Related Links

http://www.collagenmatrix.com

CONTINUE READING
dermapace-product.jpg
BiologicsTop Stories

SANUWAVE Appoints Alat Medika Indonesia as Distributor for dermaPACE and Liaison to Clinical Trials Participation for Company’s Wound Care Product(s) in Indonesia

July 20, 2017 OrthoSpineNews

SUWANEE, GA–(Marketwired – Jul 20, 2017) – SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the Company has appointed Alat Medika Indonesia as distributor for dermaPACE® and liaison for clinical trials participation for Company’s wound care product in Indonesia. The expected revenue from this agreement will be north of $1 million over the next three years.

André Mouton, V.P. International Sales and Relations of SANUWAVE, stated, “This decision to engage Alat Medika Indonesia was made to increase our focus and visibility within Indonesia for the wound care market. It is of the utmost importance that we partner with distributors that have influence and a good track record within the Indonesian market. It is well known that diabetes and related concerns need to be addressed within Indonesia and having access to outstanding technology such as SANUWAVE’s within the country is a positive step. We will need speedy access to potential clinical trials to ensure we add value with our product offering as well as clinical proven outcome. These factors will lead to faster market entry and closer ties with identified Key Opinion Leaders (KOLs),” concluded André Mouton.

Christian Hainsch, Chief Product Officer of Alat Medika International Group, declared, “Setting the ‘PACE®‘ in wound healing in Indonesia! A technical milestone in professional wound healing is coming to Indonesia. With dermaPACE, SANUWAVE developed an innovative medical device for patients suffering from diabetic wounds, ulcer or burn injuries. One of the major indications for the use of dermaPACE, and most important for Indonesia, is the treatment of diabetic ulcers. With dermaPACE the regeneration process of tissue from chronic wounds is increased and can be an alternative to amputation or medication based treatment. Diabetes and other patients benefit from a simple, painless and side-effect free treatment for faster healing and quicker recovery to improve quality of life,” concluded Mr. Hainsch.

SANUWAVE is using this occasion to further educate on our lead wound care product dermaPACE. This Extracorporeal Shockwave Technology (ESWT) device, based upon electrohydraulic principles, is CE Marked and has enjoyed success in certain markets within the European Union treating a wide variety of skin conditions such as pressure ulcers, burns, post-operative wounds, and scar reduction. dermaPACE has been proven, in two US based clinical trials enrolling 336 subjects, to be safe and effective in the treatment of Diabetic Foot Ulcers. Within a few weeks of initial treatment, wounds treated with dermaPACE reduce in area at superior rates compared to control subjects. dermaPACE exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment. The use of dermaPACE allows the clinician to more easily, and more cost-effectively, manage wounds. More importantly, the patient’s quality of life improves significantly.

For more information on SANUWAVE’s technology, please read our blog, “Shock This”, on our website at www.sanuwave.com.

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

About Alat Medika Indonesia
Being a reliable partner for hospitals, doctors and health care facilities, Alat Medika Group Indonesia brings the best medical devices to Indonesia. Serving the health care market with dedication, passion and highest quality technology standards the expert team of Alat Medika provides local medical practitioners, clinics and hospitals with a full range of medical devices ranging from laboratory equipment to radiology, sonography, laser technology for diagnostics, therapy and health care. Our team of technical and medical experts helps customers all over Indonesia to identify their needs, supply best in class medical devices and maintain and service the health care infrastructure.

Contact:
PT. Alat Medika Indonesia
Graha Mustika Ratu Bldg. 10th Floor
Jl. Jend. Gatot Subroto Kav. 74-75
Jakarta 12870 – Indonesia
sales@almed-indonesia.com
Phone: +62 21 83708874

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

CONTACT INFORMATION

  • Contact:

    Millennium Park Capital LLC
    Christopher Wynne
    312-724-7845
    cwynne@mparkcm.com

    SANUWAVE Health, Inc.
    Andre Mouton
    Vice President International Sales and Relations
    +1-615-823-9907 (Cell)
    +1-678-569-0881(Fax)
    Skype: andre.w.mouton
    Andre.Mouton@sanuwave.com

CONTINUE READING
1467292.jpeg
Spine

If You Have Lumbar Spinal Stenosis, There’s an Exciting New Option

July 20, 2017 OrthoSpineNews

July 18, 2017 / By Family Health Team

If you’ve struggled with lumbar spinal stenosis (LSS), you know it can impact your life. People with severe LSS often can’t stand longer than a few minutes or walk more than a few hundred feet without feeling severe pain.

Bulging disk and/or enlargement of the ligaments in your spine can cause LSS. When the spinal canal narrows, it causes nerve compression. When someone with LSS stands or walks, the spinal canal narrows even more, causing low back and leg pain that is relieved with sitting or bending forward.

Until a few years ago, the only treatment options available were either of two extremes: conservative therapies or open spine surgery.

Weighing treatment options for LSS

However, conservative treatments, such as NSAIDS, physical therapy and epidural steroid injections, only work for a fraction of people. Also, when they do work, the effect is often not sustained and requires repeated treatments.

Open spine surgery, on the other hand, works to relieve pressure on spinal nerves, but surgery and anesthesia may carry increased risk in older patients.

Now, there’s a new outpatient option called mild®, which stands for minimally invasive lumbar decompression. It is only an option for patients who have significant LSS due to thickening of the ligamentum flavum, or ligaments of the spine.

 

READ THE REST HERE

CONTINUE READING

Newer Posts

Older Posts